Search results for "ocular hypertension"

showing 10 items of 59 documents

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Hemin, an inducer of heme oxygenase-1, lowers intraocular pressure in rabbits.

2007

Carbon monoxide (CO) generated from heme may induce vasodilation and exert cyto-protective properties in the eye. This study was undertaken to investigate the effects of hemin, a potent inducer of heme oxygenase-1 (HO-1), on models of ocular hypertension in rabbits.Ocular hypertension was induced by injecting alpha-chymotrypsin in both eyes under local anesthesia. Only rabbits with an intraocular pressure (IOP) of 25 mmHg or more were used. The dose-response study of the hemin effect on IOP was made by an intravenous injection of the drug (50, 75, and 100 mg/kg) and subsequent IOP monitoring every 6 h. A separate set of animals was pretreated with the HO-1 inhibitor, zinc protoporphyrin-IX …

MaleIntraocular pressuregenetic structuresmedicine.drug_classOcular hypertensionProtoporphyrinsVasodilationPharmacologyBetamethasonechemistry.chemical_compoundRandom AllocationmedicineAnimalsChymotrypsinPharmacology (medical)Enzyme inducerIntraocular PressurePharmacologyAnalysis of VariancebiologyDose-Response Relationship Drugmedicine.diseaseeye diseasesHeme oxygenaseOphthalmologyDisease Models AnimalchemistryAnesthesiaEnzyme InductionInjections Intravenousbiology.proteinCorticosteroidBetamethasoneHeminOcular Hypertensionsense organsRabbitsHeme Oxygenase-1Heminmedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study.

2011

Glaucoma is a chronic neurodegenerative disease and one of the leading causes of blindness. Autoantibody based immune processes are assumed to be involved in its pathogenesis. However, it is still unclear to what extent autoantibody patterns found in the eye (aqueous humor) are congruent to systemic autoantibodies (blood). Consistency would underline the specificity of known serum antibody markers for glaucoma. In this study we used antigen microarrays to analyze autoantibody reactivities in sera and corresponding aqueous humor samples of primary open-angle glaucoma patients (N=37) and non-glaucomatous controls (N=31). Compared to control subjects several divergent immunoreactivities were i…

MalePathologymedicine.medical_specialtygenetic structuresImmunologyGlaucomaDiseaseCataract ExtractionEyePathogenesisAqueous HumorBehavioral NeuroscienceImmune systemAntigenArtificial IntelligencemedicineHumansAntigensAgedAutoantibodiesbiologyEndocrine and Autonomic Systemsbusiness.industryMicroarray analysis techniquesAutoantibodymedicine.diseaseMicroarray Analysiseye diseasesArea Under CurveImmunoglobulin GImmunologybiology.proteinFemaleOcular Hypertensionsense organsNeural Networks ComputerAntibodybusinessAlgorithmsGlaucoma Open-AngleBrain, behavior, and immunity
researchProduct

LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY: A Multicenter Study of 6,048 Eyes

2018

Purpose: To determine the incidence and risk factors for late-onset ocular hypertension (LOH) after vitrectomy. Methods: From the electronic medical records of consecutive patients who underwent primary vitrectomy, from January 2010 to December 2015, at 5 tertiary vitreoretinal centers in Italy, patient demographics, systemic, ophthalmic, operative, and postoperative data were drawn. Main outcome measure was the presence of LOH, defined as intraocular pressure >21 mmHg detected more than 2 months after vitrectomy on at least 2 consecutive visits. Results: Among 6,048 patients, LOH was found in 294 (4.9%) vitrectomized eyes and in 87 (1.4%) fellow eyes, (chi square; P < 0.001). Multiva…

MalePediatricsmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMEDLINEOcular hypertensionVitrectomyLate onset01 natural sciences03 medical and health sciences0302 clinical medicineRetinal DiseasesRisk FactorsVitrectomyHumansMedicineIntraocular PressureAgedRetrospective Studiesbusiness.industryIncidenceMedical recordIncidence (epidemiology)Retrospective cohort studyGeneral Medicinemedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryOphthalmologyItalyMulticenter study030221 ophthalmology & optometryFemaleOcular Hypertensionbusinesslate-onset ocular hypertensionFollow-Up Studies
researchProduct

Chronic social defeat stress causes retinal vascular dysfunction

2021

Abstract Purpose The roles of vascular dysfunction and chronic stress have been extensively discussed in the pathophysiology of glaucoma. Our aim was to test whether chronic stress causes retinal vascular dysfunction and therewith induces retinal ganglion cells (RGCs) loss. Methods Twelve mice underwent chronic social defeat (CSD) stress, while 12 mice received control treatment only. Intraocular pressure (IOP) was measured with a rebound tonometer. Blood plasma corticosterone concentration and adrenal gland weight were used to assess stress levels. Brn-3a staining in retinas and PPD staining in optic nerve cross sections were conducted to assess the survival of RGCs and axons respectively.…

MaleRetinal Ganglion CellsIntraocular pressuremedicine.medical_specialtyCell SurvivalRetinal ArteryVideo RecordingVideo microscopyRetinal ganglionSocial DefeatMiceTonometry OcularCellular and Molecular Neurosciencechemistry.chemical_compoundRetinal DiseasesCorticosteroneInternal medicineAnimalsMedicineChronic stressIntraocular PressureTranscription Factor Brn-3ARetinaDisorder of Sex Development 46XYAdrenal Hyperplasia CongenitalEndothelin-1business.industryOptic NerveRetinalActinsSensory SystemsMice Inbred C57BLDisease Models AnimalOphthalmologyEndocrinologymedicine.anatomical_structurechemistryChronic DiseaseOptic nerveOcular Hypertensionsense organsCorticosteronebusinessStress PsychologicalExperimental Eye Research
researchProduct

Intereye Spatial Relationship of Abnormal Neuroretinal Rim Locations in Glaucoma Patients from the Diagnostic Innovations in Glaucoma Study

2006

Purpose To determine the spatial relationship in neuroretinal rim parameter values between eyes in ocular hypertensives, glaucoma suspects, and glaucoma patients. Design Observational-cross-sectional study. Methods A total of 334 eyes of 167 patients were included. All patients underwent confocal scanning laser ophthalmoscopy imaging in both eyes. Intereye concordance ratio of abnormal rim sectors as classified by the Moorfield regression analysis (MRA) was calculated as the ratio of matching abnormal rim areas to the total number of abnormal rim areas. The amount of agreement was calculated for each sector separately. Results Of the right (left) eyes, 39 (39) eyes were classified “borderli…

MaleRetinal Ganglion Cellsmedicine.medical_specialtyIntraocular pressuregenetic structuresConcordanceOptic DiskVision DisordersGlaucomaOphthalmoscopyNerve FibersOphthalmologyOptic Nerve DiseasesmedicineHumansProspective StudiesProspective cohort studyIntraocular PressureAgedmedicine.diagnostic_testbusiness.industryLasersMiddle Agedmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologyCross-Sectional StudiesNeuroretinal rimDisease ProgressionOptometryFemaleOcular Hypertensionsense organsVisual FieldsAbnormalitybusinessGlaucoma Open-AngleKappaAmerican Journal of Ophthalmology
researchProduct

Analysis of Autoantibody Repertoires in Sera of Patients with Glaucoma

2003

PURPOSE Glaucoma is the second cause of blindness worldwide. It is usually considered a neurodegenerative disease. There is evidence that an autoimmune mechanism is involved in the development of glaucoma in some patients. The aim of this study was to analyze the IgG autoantibody repertoires in sera of glaucoma patients and healthy subjects. METHODS A total of 82 patients were divided into four groups: healthy volunteers without any ocular disorders (CO, n = 30), patients with primary open-angle glaucoma (POAG, n = 19), ocular hypertension (OHT, n = 16), and normal tension glaucoma (NTG, n = 17). All groups were matched for age and gender. The sera of these patients were tested against West…

MaleRetinal Ganglion Cellsmedicine.medical_specialtygenetic structuresEye diseaseBlotting WesternOcular hypertensionGlaucomaAutoantigens03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigenOphthalmologyNormal tension glaucomamedicineHumansIntraocular PressureAgedAutoantibodiesbiologybusiness.industryAutoantibodyRetinalGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesOphthalmologychemistryCase-Control StudiesImmunoglobulin GMultivariate AnalysisImmunology030221 ophthalmology & optometrybiology.proteinFemaleOcular Hypertensionsense organsAntibodybusinessGlaucoma Open-Angle030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct